{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:58:53Z","timestamp":1781578733870,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.pnpbp.2018.01.003","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T18:00:21Z","timestamp":1515175221000},"page":"86-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Targeting cytokines in reduction of depressive symptoms: A comprehensive review"],"prefix":"10.1016","volume":"83","author":[{"given":"Aisha S.","family":"Shariq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Brietzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishalinee","family":"Barendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7354","key":"10.1016\/j.pnpbp.2018.01.003_bb5040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/475027a","article-title":"Grand\u00a0challenges\u00a0in\u00a0global mental health","volume":"475","author":"Collins","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.01.003_bb0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.01.003_bb5000","first-page":"262","article-title":"The effect of infliximab on depressive symptoms in patients with ankylosing spondylitis","volume":"40","author":"Ers\u00f6zl\u00fc-Bozk\u0131rl\u0131","year":"2015","journal-title":"Acta Reumatol. Port."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.01.003_bb0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00296-010-1616-x","article-title":"Infliximab, a TNF-\u03b1 antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level","volume":"32","author":"Ertenli","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.01.003_bb0045","first-page":"459","article-title":"Novel investigational drugs targeting IL-6 signaling for the treatment of depression","volume":"24","author":"Fonseka","year":"2015"},{"key":"10.1016\/j.pnpbp.2018.01.003_bb0050","first-page":"205","article-title":"The association of electroconvulsive therapy to pharmacological treatment and its influence on cytokines","volume":"92","author":"Freire","year":"2017"},{"key":"10.1016\/j.pnpbp.2018.01.003_bb5035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2017.06.006","article-title":"Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases","volume":"85","author":"Gadina","year":"2017","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.01.003_bb5020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1440-1819.2008.01918.x","article-title":"Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder","volume":"63","author":"Grassi-Oliveira","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.01.003_bb0060","doi-asserted-by":"crossref","first-page":"e60435","DOI":"10.1371\/journal.pone.0060435","article-title":"Depressive symptoms in crohn's disease: relationship with immune activation and tryptophan availability","volume":"8","author":"Guloksuz","year":"2013","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.01.003_bb5030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10620-014-3375-0","article-title":"Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease","volume":"60","author":"Horst","year":"2015","journal-title":"Dig. Dis. Sci."},{"issue":"8","key":"10.1016\/j.pnpbp.2018.01.003_bb5025","doi-asserted-by":"crossref","first-page":"1315-23.e2","DOI":"10.1016\/j.cgh.2013.10.019","article-title":"Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases","volume":"12","author":"Kappelman","year":"2014","journal-title":"Clin. Gastroenterol Hepatol."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.01.003_bb0065","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1159\/000350094","article-title":"Molecular mechanisms of depression: perspectives on new treatment strategies","volume":"31","author":"Lang","year":"2013","journal-title":"Cell. Physiol. Biochem."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.01.003_bb0070","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1210\/endo.135.2.7518383","article-title":"Local administration of recombinant human interleukin-1 beta in the rat hippocampus increases serotonergic neurotransmission, hypothalamic-pituitary-adrenocortical axis activity, and body temperature","volume":"135","author":"Linthorst","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.pnpbp.2018.01.003_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbi.2013.04.004","article-title":"Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression","volume":"31","author":"Mehta","year":"2013","journal-title":"Brain Behav. Immun."},{"issue":"11","key":"10.1016\/j.pnpbp.2018.01.003_bb0085","doi-asserted-by":"crossref","first-page":"700","DOI":"10.14423\/SMJ.0000000000000554","article-title":"Deep brain stimulation for treatment-refractory depression","volume":"109","author":"Narang","year":"2016","journal-title":"South. Med. J."},{"issue":"14","key":"10.1016\/j.pnpbp.2018.01.003_bb0090","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2174\/1381612823666170111144340","article-title":"Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD","volume":"23","author":"Pan","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2018.01.003_bb0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/7854_2016_7","article-title":"Depression in Autoimmune Diseases","volume":"31","author":"Pryce","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.01.003_bb0105","first-page":"31","article-title":"A randomized controlled trial of the tumor necrosis factoR antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMAPsychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.01.003_bb5015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.psc.2015.09.006","article-title":"Bipolar disorder and inflammation","volume":"39","author":"Rosenblat","year":"2016","journal-title":"Psychiatr. Clin. North Am."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.01.003_bb0110","first-page":"162","article-title":"Changes of cytokine profiles during electroconvulsive therapy in patients with major depression","volume":"29","author":"Rotter","year":"2013"},{"issue":"16","key":"10.1016\/j.pnpbp.2018.01.003_bb0115","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00213-017-4634-5","article-title":"Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data","volume":"234","author":"Sakurai","year":"2017","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2018.01.003_bb0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2893.2010.01393.x","article-title":"Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update","volume":"18","author":"Sockalingam","year":"2011","journal-title":"J. Viral Hepat."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.01.003_bb5010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.bbr.2012.07.026","article-title":"Novel therapeutic targets in depression: minocycline as a candidate treatment","volume":"235","author":"Soczynska","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2018.01.003_bb0130","article-title":"Rodent models of depression: neurotrophic and neuroinflammatory biomarkers","volume":"932757","author":"Stepanichev","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"10","key":"10.1016\/j.pnpbp.2018.01.003_bb5005","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.38091","article-title":"Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus","volume":"65","author":"Szepietowski","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.01.003_bb0140","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.euroneuro.2016.02.003","article-title":"Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression\u2014the EMC trial","volume":"26","author":"Tadi\u0107","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.01.003_bb0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1440-1819.2008.01905.x","article-title":"Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorder in patients with rheumatoid arthritis","volume":"63","author":"Uguz","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2018.01.003_bb0155","article-title":"Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia","author":"Wang","year":"2017","journal-title":"Bipolar Disorder, and Depression"},{"key":"10.1016\/j.pnpbp.2018.01.003_bb0160","first-page":"193","article-title":"Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation","volume":"47","author":"Weinberger","year":"2015"},{"key":"10.1016\/j.pnpbp.2018.01.003_bb0165","article-title":"Effect of antidepressant treatment on peripheral inflammation markers - A meta-analysis","author":"Wi\u0119d\u0142ocha","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2018.01.003_bb0175","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrn.2016.69","article-title":"Integrating neuroimmune systems in the neurobiology of depression","volume":"17","author":"Wohleb","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"issue":"22","key":"10.1016\/j.pnpbp.2018.01.003_bb0180","doi-asserted-by":"crossref","first-page":"e3816","DOI":"10.1097\/MD.0000000000003816","article-title":"Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists","volume":"95","author":"Wu","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.01.003_bb0190","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12325-016-0455-x","article-title":"Sirukumab: A Potential Treatment for Mood Disorders?","volume":"34","author":"Zhou","year":"2017","journal-title":"Adv. Ther."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617308862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617308862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T11:19:08Z","timestamp":1751195948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584617308862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":33,"alternative-id":["S0278584617308862"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.01.003","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cytokines in reduction of depressive symptoms: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}